Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
V110, pneumococcal vaccine polyvalent · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| V110, pneumococcal vaccine polyvalent | BIOLOGICAL | - |
Inclusion Criteria: * Males and females in good health, ages 20-40, with no history of pneumococcal vaccination Exclusion Criteria: * Subjects with a recent febrile illness * Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chem...
V110 is an investigational pneumococcal vaccine being studied for the prevention of pneumococcal infection in healthy adults. It is a monoclonal antibody modality developed by Merck & Company, Inc. (MRK). The vaccine is intended to protect against diseases caused by Streptococcus pneumoniae bacteria.
V110 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical trials to evaluate the safety and immunogenicity of V110 in healthy adult populations.
V110 is currently in Phase 3 clinical development. Two Phase 3 trials have been completed, including a study of V110 in healthy adults and a study of V110 co-administered with a booster dose of the mRNA-1273 COVID-19 vaccine. V110 remains investigational and is not yet approved.
V110 has been evaluated in two completed Phase 3 clinical trials. NCT00127153 studied V110 as a pneumococcal vaccine in 130 healthy adults. NCT05158140 evaluated the safety, tolerability, and immunogenicity of V110 co-administered with a booster dose of mRNA-1273 in 850 healthy adults aged 50 years and older.
V110 and V114 are distinct investigational pneumococcal vaccines, though they are both being developed by Merck. In clinical trial NCT05158140, V110 was studied alongside V114, with both vaccines co-administered with a booster dose of mRNA-1273 in healthy adults. They are separate vaccine candidates.